First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
Precision Medicine Online

CRISPR Therapeutics' Gene-Editing Drug Cuts LDL Cholesterol, Triglycerides in Early Human Trial

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...